Q2 in line: sales up 11% y-o-y, adj. EBIT margin 37% (24%) Guides for -0.
Redeye gives an initial take on the positive phase IIa results in RVO with ANXV, an imporant milesto...
AAC Clyde Space offers exposure to the fast-growing low Earth orbit space market.
Redeye is optimistic about today’s news from Egetis Therapeutics that patients on Emcitate are assoc...
Train Alliance redovisade stigande omsättning och resultat under det andra kvartalet.
We initiate coverage of LapWall with a BUY-rating and TP of EUR 3.
Biosergen has together with Indian Alkem initiated patient studies with its drug candidate BSG005 fo...
Spago Nanomedical’s Phase I/IIa study, Tumorad-01, is progressing with a steady OPEX base in line wi...
Redeye comments on Modelon's Q2 2024 report, which was in line with our expectations.
Redeye comments on Flexion Mobile's Q2 2024 report, which was in line with our expectations.
Redeye saw a Q2 report showing sales slightly below our estimates, with a total growth of 31% for th...
Q2 EBIT of SEK 34m, +41% vs. ABGSC but -21% vs. consensus AUM 2% above forecast, positive for revisi...
Redeye states that Q2 came in weaker than it had expected, although the reason continues to be a ver...
Redeye reiterates its valuation following the Q2 2024 report, which was stronger than our expectatio...
2024e estimates raised by 1-2% on order phasing We're above guidance midpoint but expect unchanged F...
